Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmpaSema
NCT04061200Phase 4Unknown
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in diabetic nephropathy (DN) comparing Semaglutide + Empagliflozin with Placebo + Empagliflozin (2 arms). Primary endpoint: Change in Albuminuria at 52 weeks. Status: unknown.
02
Drugs
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04061200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061200.